89Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma-Reference-Cited by-同舟云学术

89Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma

Published:2019-06 Issue:5 Volume:34 Page:288-296
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Benedetto Raquel¹,Massicano Adriana V.F.²,Crenshaw Bryant K.²,Oliveira Renato³,Reis Rui M.³,Araújo Elaine B.¹,Lapi Suzanne E.²

Affiliation:

1. Instituto de Pesquisas Energéticas e Nucleares (IPEN), Sao Paulo, Brazil.

2. Department of Radiology, University of Alabama at Birmingham (UAB), Birmingham, Alabama.

3. Molecular Oncology Research Center, Barretos Cancer Hospital, Sao Paulo, Brazil.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2018.2616

Reference59 articles.

1. A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects

2. Antibody diversity: A link between switching and hypermutation

3. Designing the Magic Bullet? The Advancement of Immuno-PET into Clinical Use

4. Antibody Conjugates and Therapeutic Strategies

5. Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review;Frontiers in Oncology;2024-08-22

2. Preparation, quality control, and absorbed dose estimation of 89Zr-DFO-Cetuximab for imaging of EGFR-expressing tumors;Journal of Radioanalytical and Nuclear Chemistry;2024-04-26

3. ImmunoPET Targeting Receptor Tyrosine Kinase: Clinical Applications;Cancers;2023-12-18

4. [89Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models;Cancers;2023-05-11

5. 89Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model;Scientific Reports;2022-11-10